Glucocorticosteroids for viral hepatitis C

Cochrane Database of Systematic Reviews

Volumn 2009, Issue 1, 2004, Pages

  Brok, Jesper ^a   Mellerup, Martin Thyge ^b   Krogsgaard, Kim ^c   Gluud, Christian ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b PhaseOneTrials A/S ^*  (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GLUCOCORTICOID; INTERFERON;

ACUTE DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HEPATITIS C; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACUTE DISEASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RANDOMIZED CONTROLLED TRIALS;

EID: 3843050445     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002904.pub2     Document Type: Article

References (77)

1. Chayama K, Tsubota A, Kobayashi M, Hashimoto M, Miyano Y, Koike H, et al. A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C. Hepatology 1996;23(5):953-7.
2. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type 2 mixed cryoblobulinemia. Blood 1994;84(10):3336-43.
3. Guilera M, Forns X, Torras X, Enriques J, Coll S, Sola R, et al. Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. Journal of Hepatology 2000;33(1):135-41.
4. Liaw YF, Sheen IS, Lin SM, Chen TJ. Prednisolone withdrawel followed by recombinant alfa-interferon in chronic non-A, non-B hepatitis. Gastroenterologia Japonica 1991;26 Suppl:3247-50.
5. Liaw YF, Sheen IS, Lin SM, Chen TJ, Chu CM. Effects of prednisolone pretreatment in interferon alfa therapy for patients with chronic non-A, non-B hepatitis. Liver 1993;13(1):46-50.
6. Mazzaro C, Panarello G, Carniello S, Faelli A, Mazzi G, Crovatto M, et al. Interferon versus steroids in patients with hepatitis C virus associated cryoglobulinaemic glomerulonephritis. Digestive and Liver Disease 2000;32(8):708-15.
7. McHutchison JG, Ponnudurai R, Bylund DL, Anguiano A, Pockros PJ, Modala T, et al. Prednisone withdrawel followed by interferon alpha for treatment of chronic hepatitis C infection. Journal of Clinical Gastroenterology 2001;32(2):133-7.
8. McHutchison JG, Wilkes LB, Pockros PJ, Chan CS, Neuwald P, Urdea M, et al. Pulse corticosteroids therapy increases viremia (HCV RNA) in patients with chronic HCV infection [abstract]. Journal of Hepatology 1993;18 (4 pt 2):87A.
9. Mondazzi L, Bellobuono A, Rezakovic I, Minola E, Idéo G. Lymphoid alpha-IFN plus prednisone treatment of anti-HCV positive chronic hepatitis [abstract]. Journal of Hepatology 1993;18 Suppl (1):150A.
10. Stokes P, Lopez WC, Balart LA. Effects of short-term corticosteroid therapy in patients with chronic non-A, non-B hepatitis [abstract]. Gastroenterology 1987;92(5):1783A.
11. Anonymous. Steroids in chronic B-hepatitis. A randomised, double-blind, multinational trial on the effect of low-dose, long-term treatment on survival. Liver 1986;6(4):227-32.
12. Brook MG, Main J, Yap I, Chan G, Karayiannis P, Crosey M, et al. Prednisolone withdrawal followed by lymphoblastoid interferon alpa in the therapy of adult patients with presumed childhood acquired chronic hepatitis B virus infection. Alimentary Pharmacology & Therapeutics 1993;7(3):331-6.
13. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. The Quarterly Journal of Medicine 1971;40(158):159-85.
14. Giacchino R, Facco F, Giambartolomei G, Navone C, Timitilli A, Cirillo C, et al. Treatment of children with chronic hepatitis B with a combinations of steroids and human lymphobastoid interferon. Chemioterapia 1988;7 Suppl:320-5.
15. Giacchino R, Main J, Timitilli A, Giambartolomei G, Facco F, Cirillo C, et al. Dual-centre, double-blind, randomsed trial of lymphoblasoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15(3):143-8.
16. Gregorio GV, Jara P, Hierro L, Diaz C, de la Vega A, Vegnente A, et al. Lymphoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B. Hepatology 1996;23(4):700-7.
17. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986;6(2):173-9.
18. Hoofnagle JH, Davis GL, Pappas SC, Hanson RG, Peters M, Avigan MI, et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomised double-blind, placebo-controlled trial. Annals of Internal Medicine 1986;104(1):12-7.
19. Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM, Bassendine M, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. Journal of Hepatology 1996;25(6):803-13.
20. Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM, Bassendine M, et al. Pretreatment with prednisolone enhance the effect of human lymphoblastoid interferon in chronic hepatitis B. Ugeskrift for Laeger 1998;160(39):5657-71.
21. Lam KC, Lai CL, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. The New England Journal of Medicine 1981;304(7):380-6. [MEDLINE: 81098828]
22. Lauta VM, De Sangro MA. Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of type 2 mixed essential cryoglobulinemia. Medical Oncology 1995;12(4):223-30.
23. Lee SD, Tong MJ, Wu JC, Lin HC, Tsai YT, Lo KJ. A randomised double-blind placebo-controlled trial of prednisolone therapy in HBeAg and HBV DNA positive Chinese patients with chronic active hepatitis B. Journal of Hepatology 1991;12(2):246-50. [MEDLINE: 91268491]
24. Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid pretreatment on the treatment of chronic type B hepatitis in Asians. Journal of Hepatology 1994;20(2):175-80.
25. Liaw YF, Lin SM, Sheen IS, Chen TJ, Chu CM. Treatment of chronic type B hepatitis in Southeast Asia. The American Journal of Medicine 1988;29(85 (2A)):147-9.
26. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994;19(2):273-9. [MEDLINE: 94124105]
27. Manzillo G, Piccinino F, Sagnelli E, Izzo CM, Pasquale G, Maio G, et al. Treatment of HBsAg-positive chronic hepatitis with corticosteroids and/or azathioprine. A prospective study. Ricerca in Clinica e in Labarotorio 1983;13(2):261-8.
28. Murray LI, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1(7806):735-7.
29. Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Preospective randomised controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon-alpha alone in patinets with chronic active hepatitis B. The European Journal of Medicine 1992;1(7):396-402.
30. Perez V, Findor J, Tanno H, Sorda J. A controlled trial of high dose of interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B. Gut 1993;34 Suppl (2):91-4.
31. Schvarcz R. Chronic posttranfusion non-A, non-B hepatitis and autoimmune chronic active hepatitis-aspects on treatment, prognosis and relation to hepatitis C virus. Scandinavian Journal of Infectious Diseases 1991;79:791-848.
32. Sjögren MH, Hoornagle JH, Waggoner JG. Effects of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology 1987;7(3):582-5.
33. Ware AJ, Jones RE, Shorey JW, Combes B. A controlled trial of steroid therapy in massive hepatic necrosis. The American Journal of Gastroenterology 1974;62(2):130-3.
34. Ware AJ, Cuthbert JA, Shorey JW, Gurian LE, Eigenbrodt EH, Combes B. A prospective trial of steroid therapy in severe viral hepatitis. The prognostic significance of bridging necrosis. Gastroenterology 1981;80(2):219-24.
35. Weller IV, Bassendine MF, Murray AK, Craxi A, Thomas HC, Sherlock S. Effects of prednisolone/azathioprine in chronic hepatitis B viral infection. Gut 1982;23:650-5.
36. Wu PC, Lai CL, Lam KC, HO J. Prednisole in HBsAg-positive chronic active hepatitis: histologic evaluation in a controlled prospective study. Hepatology 1982;2(6):777-83.
37. Zarski JP, Causse X, Cohard M, Cougnard J, Trepo C. A randomised, controlled clinical trial of interferon alpa 2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. Journal of Hepatology 1994;20(6):735-41.
38. Alberti A, Bortolotti F. Hepatitis C. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rodés J editor(s). Oxfort Textbook of Clinical Hepatology. Second Edition. Vol. 1, Oxford: Oxford University Press, 1999:903-22.
39. Alberti A, Benvegùe L. Management of hepatitis C. Journal of Hepatology 2003;38 Suppl (1):104-18.
40. Alter HJ, Purcell RH, Shih JW. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. The New England Journal of Medicine 1989;321:1494-500.
41. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology 1999;31(5):929-38. [MEDLINE: 20046538]
42. Bell TM, Bansal AS, Shorthouse C, Sandford N, Powell EE. Low-titre auto-antibodies predict autoimmune disease during interferon-alfa treatment of chronic hepatitis C. Journal of Gastroenterology and Hepatology 1999;14(5):419-22.
43. Belli LS, Alberti AB, Rondinara GF, de Carlis L, Corti A, Mazza E, et al. Early ribavirin treatment and avoidance of corticosteroids in hepatitis C virus (HCV)-positive liver transplant recipients: interim report of a prospective randomized trial. Transplantation Proceedings 2001;33(1-2):1353.
44. Booth JC, Brown JL, Thomas HC. The management of chronic hepatitis C virus infection. Gut 1995;37(4):449-54. [MEDLINE: 96097868]
45. Brok J, Kjaergard LL, Gluud C. Interferon alpha plus ribavirin versus interferon alpha for chronic hepatitis C - an updated systematic Cochrane review. Journal of Hepatology 2003;38 Suppl (2):129A.
46. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. Journal of Hepatology 1996;24(3):308-12. [MEDLINE: 96265228]
47. Deeks JJ, Bradburn MJ, Localio R, Berlin J. Much ado about nothing: meta-analysis for rare events [abstract]. Proceedings of 2nd symposium on systematic reviews: beyond the basics. www.ihs.ox.ac.uk/csm/talks.html#p23 (accessed 16/2 2004) 1999:23.
48. DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341-50.
49. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
50. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26 Suppl (1)(3):112-21.
51. Egger M, Davey Smth G, Schneider M, Minder C. Bias in meta-analysis detected by a simple grapical test. British Medical Journal 1997;315(7109):629-34.
52. El-Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 2003;36(6):1439-45.
53. Fabbri C, Jaboli MF, Giovanelli S, Azzaroli F, Pezzoli A, Accogli E, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World Journal of Gastroenterology 2003;9(7):1487-90.
54. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Alimentary Pharmacology & Therapeutics 2003;18(6):549-58.
55. Ferri C, Zignego AL, Pileri SA. Cryoglobulins. Journal of Clinical Pathology 2002;55:4-13.
56. Filipponi F, Salizzoni M, Grazi G, Pisati R, Ferrara R. Study of simulect-based, steroid-free immunosuppressive regimen in HCV de novo liver transplant patients: preliminary results. Transplantation Proceedings 2001;33(7-8):3211-12.
57. Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. The New England Journal of Medicine 1976;294(13):681-7. [MEDLINE: 76126031]
58. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. The Cochrane Library 2002, Issue 3.
59. Hougardy DMC, Peterson GM, Bleasel MD, Randall CTC. Is enough attention being given to the adverse effects of corticosteroids therapy. Journal of Clinical Pharmacy and Therapeutics 2000;25:227-34.
60. International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonization Guidelines. Parexel/Barnett, 1997.
61. Jarlbæk L, Gram LF, Arnberg A. Adverse events in short-term steroid therapy. Which adverse events can be expected during daily administration of 20 to 40 mg prednisolone for a period of 1-3 weeks [Bivirkninger ved kortvarig steroidbehandling]. Ugeskraeft for Laeger 2000;162(4):528-9.
62. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. British Medical Journal 2001;323(7303):42-6.
63. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
64. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha interferon for chronic hepatitis C. The Cochrane Library 2003, Issue 4.
65. Krawitt EL. Autoimmune hepatitis [see comments]. The New England Journal of Medicine 1996;334(14):897-903. [MEDLINE: 96175830]
66. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244(4902):362-4. [MEDLINE: 89222455]
67. Lambiase L, Davis GL. Treatment of chronic hepatitis. Gastroenterology Clinics of North America 1992;21(3):659-77. [MEDLINE: 92387776]
68. Magy N, Cribier B, Schmitt C, Ellero B, Jaeck D, Boudjema K, et al. Effects of corticosteroids on HCV infection. International Journal of Immunopharmacology 1999;21(4):253-61. [MEDLINE: 99335118]
69. Mellerup MT, Krogsgaard K, Mathurin P, Gluud C, Poynard T. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. The Cochrane Library 2003, Issue 4.
70. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13. [MEDLINE: 98417104]
71. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for acute hepatitis C. The Cochrane Library 2003, Issue 4.
72. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. The Journal of the American Medical Association 1995;273(5):408-12.
73. Thiele DL, DuCharme L, Cunningham MR, Mimms LT, Cuthbert JA, Lee WM, et al. Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. The American Journal of Gastroenterology 1996;91(2):300-8. [MEDLINE: 96189990]
74. Tisone G, Angelico M, Palmieri G, Pisani F, Anselmo A, Baiocchi L, et al. A pilot study on the safety of immunosuppression without prednisone after liver transplantation. Transplantation 1999;67(10):1308-13.
75. Tygstrup N, Andersen PK, Juhl E. Steroids in chronic B hepatitis. A randomized, double-blind, multinational trial on the effect of low-dose, long-term treatment on survival. A trial group of the European Association for the Study of the Liver. Liver 1986;6(4):227-32. [MEDLINE: 87038630]
76. WHO. Fact sheet N 164. http://www.who.int/inf-fs/en/fact164.html June 1997 (accessed 16/2 2004).
77. WHO Press Release. Hepatitis C: 170 million affected worldwide and still no vaccine. http://www.who.int/emc/diseases/hepatiti/index.html 1 May 1998.